CPT code 44100 designates a minimally invasive diagnostic procedure in which a capsule is introduced orally to obtain biopsy samples from the small intestine. The code represents a targeted approach to small-bowel tissue sampling that can aid diagnosis of inflammatory, infectious, and neoplastic conditions when traditional endoscopy is limited. Nationally, accurate coding of this service matters for procedural reporting, clinical registries, and alignment of facility and professional claims.

Key payers covered in the analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of clinical context for capsule-based small-bowel biopsy, common sites of service for billing, typical service descriptors, and the set of common claim modifiers used with the code. The publication also summarizes benchmark usage patterns where available, highlights relevant policy and billing considerations affecting coverage and payment, and outlines implications for coding compliance and documentation.

This national summary is intended for revenue cycle leaders, coding professionals, gastroenterology clinicians, and payers seeking clarity on procedural identification, reporting practices, and the operational setting for CPT code 44100. Data not available in the input.